Xcout Intel
Origin
Origin Bio operates a tissue-first data and model platform that maps cancer biology using patient tumor samples. The company generates spatial, molecular, and functional maps from real tumor tissue to support target discovery, drug response prediction, and multimodal AI modeling for researchers and life sciences partners.
Subscribe to see Origin’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Origin at a glance
Origin is a biotech company headquartered in United States. It has raised at least $5.5M across the 3 funding rounds on record. Its most recent funding round raised $500,000 in June 2022. Xcout recorded 5 job postings from Origin in the last 90 days.
Origin funding rounds
At least $5.5M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $500,000 | — | |
| SEC Form D filing | $1.3M | — | |
| SEC Form D filing | $3.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Origin
Xcout recorded 5 job postings from Origin in the last 90 days, from a hiring record Xcout has kept since May 2026.
The weekly hiring trend, the roles and locations behind it — see Origin's hiring signals →
Origin competitors
A few of Origin's closest competitors — see the full list of competitors and alternatives →
Parallel Bio provides a human-first drug discovery and precision medicine platform that maps human biology using patient samples and computational tools. The company serves pharmaceutical and biotechnology organizations by conducting faster, animal-free preclinical testing and generating proprietary human biological data.
Lifesenz Cancer is a biomedical organization that develops 3D cell culture systems and patient-derived ex vivo models to predict individual chemotherapy responses and guide precision cancer therapy. The company also provides biopharmaceutical R&D training, workshops, and educational programs for students, researchers, and job seekers to bridge the gap between academia and industry.
WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Indivumed GmbH is a precision oncology company that provides tumor and normal tissue samples, multi-omics and clinical data databases, biomathematical and AI tools, and patient-derived cellular models. The company serves researchers and pharmaceutical partners by conducting cancer target discovery, target validation, and therapeutic drug development.
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Blank Bio is an applied AI research lab founded in 2025 and headquartered in San Francisco, California. The company builds RNA foundation models to learn patterns linked to disease, providing RNA intelligence for precision oncology and medicine.
Get Origin's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Origin in Xcout Intel
- 3 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access